You are here: Industry Insights > Opdivo

News List

Merck's Keytruda looks to zoom past Opdivo with fast head and neck cancer review fiercepharma
February 12, 2019
Merck & Co.’s Keytruda is duking it out with Bristol-Myers Squibb’s Opdivo in the head and neck cancer marketplace, but Keytruda just took one step toward a green light that would give it a big edge.
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma worldpharmanews
January 17, 2019
This decision represents the first approval of an Immuno-Oncology (I-O) combination therapy for patients with this type of cancer in the European Union.
BMS gets new OK for Opdivo/Yervoy in kidney cancer pharmaphorum
January 17, 2019
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carcinoma (RCC), the most common form of kidney cancer.
BMS looks to RNA splicing to boost immunotherapies pharmaphorum
December 19, 2018
Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to.....
NICE turns down Opdivo/Yervoy combo for kidney cancer pharmatimes
December 11, 2018
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
SMC accepts four medicines for NHS use pharmatimes
December 11, 2018
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
NHS funds BMS’ Opdivo to prevent skin cancer returning pharmaphorum
December 03, 2018
NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year to reject the drug in this indication.
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund pharmafile
December 03, 2018
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer Drugs Fund as a treatment option for melanoma, NICE has revealed...
NICE u-turn on Opdivo for skin cancer recurrence pharmatimes
November 30, 2018
NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the National Institute for Health and Care Excellence...
BMS' Opdivo+Yervoy combo fails in small cell lung cancer pharmafile
November 28, 2018
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page